Patients' Characteristics and PCR Results
| Patient . | Clinical Status . | LYM . | CD19+ . | CD34+ . | CD34+/ . | bcl-2/IgH PCR . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | (%) . | (%) . | (%) . | CD19+ . | MNC . | CD34− . | CD34−/ . | CD34+ . | CD34+/ . | CD34+/ . |
| . | . | . | . | . | . | (%) . | . | . | CD19+ . | . | CD19+ . | CD19− . |
| B.K. | PBSCT | CR | 17 | 10.5 | 0.9 | 28.1 | Pos | Pos | Pos | Neg | Neg | Neg |
| F.G. | Post-Mob | PR | NA* | 17.3 | 1.85 | 30.8 | Pos | Pos | Pos | Neg | Neg | Neg |
| B.S. | PBSCT | Relapse | 13 | NA | 0.05 | 40.0 | Pos | Pos | Pos | Neg | Neg | Neg |
| G.M. | PBSCT | Relapse | 40 | 20.9 | 3.0 | 23.8 | Pos | Pos | Pos | Neg | Neg | Neg |
| K.A. | Pre-Mob | Diagnosis | NA* | 20.0 | 1.2 | 34.9 | Pos | Pos | Pos | Neg | Neg | Neg |
| W.I. | PBSCT | CR | 11 | 10.6 | 4.8 | 59.4 | Pos | Pos | Pos | Neg | Neg | Neg |
| G.G. | PBSCT | Relapse | 23* | 21.5 | 0.6 | 45.5 | Pos | Pos | Pos | Pos | Pos | Neg |
| K.G. | Pre-Mob | Relapse | NA* | 2.7 | 0.8 | 0.5 | Pos | Pos | NA | Neg | Neg | Neg |
| Z.W. | PBSCT | Relapse | 10* | 6.6 | 0.3 | 0.2 | Pos | Pos | Pos | Neg | Neg | Neg |
| R.I. | PBSCT | CR | 31 | 13.6 | 1.3 | 2.5 | Pos | Pos | NA | Neg | Neg | Neg |
| O.C. | PBSCT | CR | 31 | 17.7 | 1.5 | 25.0 | Pos | Pos | NA | Neg | Neg | Neg |
| S.K. | PBSCT | CR | 18 | 3.8 | 1.1 | 0.5 | Pos | Pos | NA | Neg | Neg | Neg |
| M.K. | Post-Mob | PR | 23* | 7.5 | 0.3 | 53.3 | Pos | Pos | NA | Neg | Neg | Neg |
| R.S. | PBSCT | CR | 27 | 8.3 | 0.5 | 43.5 | Pos | Pos | NA | Neg | Neg | Neg |
| Patient . | Clinical Status . | LYM . | CD19+ . | CD34+ . | CD34+/ . | bcl-2/IgH PCR . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | (%) . | (%) . | (%) . | CD19+ . | MNC . | CD34− . | CD34−/ . | CD34+ . | CD34+/ . | CD34+/ . |
| . | . | . | . | . | . | (%) . | . | . | CD19+ . | . | CD19+ . | CD19− . |
| B.K. | PBSCT | CR | 17 | 10.5 | 0.9 | 28.1 | Pos | Pos | Pos | Neg | Neg | Neg |
| F.G. | Post-Mob | PR | NA* | 17.3 | 1.85 | 30.8 | Pos | Pos | Pos | Neg | Neg | Neg |
| B.S. | PBSCT | Relapse | 13 | NA | 0.05 | 40.0 | Pos | Pos | Pos | Neg | Neg | Neg |
| G.M. | PBSCT | Relapse | 40 | 20.9 | 3.0 | 23.8 | Pos | Pos | Pos | Neg | Neg | Neg |
| K.A. | Pre-Mob | Diagnosis | NA* | 20.0 | 1.2 | 34.9 | Pos | Pos | Pos | Neg | Neg | Neg |
| W.I. | PBSCT | CR | 11 | 10.6 | 4.8 | 59.4 | Pos | Pos | Pos | Neg | Neg | Neg |
| G.G. | PBSCT | Relapse | 23* | 21.5 | 0.6 | 45.5 | Pos | Pos | Pos | Pos | Pos | Neg |
| K.G. | Pre-Mob | Relapse | NA* | 2.7 | 0.8 | 0.5 | Pos | Pos | NA | Neg | Neg | Neg |
| Z.W. | PBSCT | Relapse | 10* | 6.6 | 0.3 | 0.2 | Pos | Pos | Pos | Neg | Neg | Neg |
| R.I. | PBSCT | CR | 31 | 13.6 | 1.3 | 2.5 | Pos | Pos | NA | Neg | Neg | Neg |
| O.C. | PBSCT | CR | 31 | 17.7 | 1.5 | 25.0 | Pos | Pos | NA | Neg | Neg | Neg |
| S.K. | PBSCT | CR | 18 | 3.8 | 1.1 | 0.5 | Pos | Pos | NA | Neg | Neg | Neg |
| M.K. | Post-Mob | PR | 23* | 7.5 | 0.3 | 53.3 | Pos | Pos | NA | Neg | Neg | Neg |
| R.S. | PBSCT | CR | 27 | 8.3 | 0.5 | 43.5 | Pos | Pos | NA | Neg | Neg | Neg |
Abbreviations: Pos, positive; Neg, negative; PBSCT, peripheral blood stem cell transplantation; CR, complete remission; PR, partial remission; Pre-Mob, before PBSC mobilization; Post-Mob, after PBSC mobilization; NA, not available; LYM (%), proportion of lymphocytes in the BM on cytological examination.
Indicates the presence of infiltration, as shown by histopathology. The proportion of CD19 is given as % of the BM MNC and the proportion of CD34+/CD19+ cells is given as % of CD34+ cells.